Celcuity (CELC) News Today $52.28 -2.32 (-4.25%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Celcuity Inc.: Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review ProgramAugust 28 at 10:37 PM | finanznachrichten.deCelcuity stock jumps after FDA accepts gedatolisib NDA for reviewAugust 28 at 10:37 PM | za.investing.comCelcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review ProgramAugust 28 at 10:37 PM | markets.businessinsider.comCelcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review ProgramAugust 27 at 4:05 PM | globenewswire.comCelcuity, Inc. (NASDAQ:CELC) Receives $47.40 Consensus Target Price from AnalystsAugust 19, 2025 | americanbankingnews.comCelcuity price target raised to $66 from $50 at H.C. WainwrightAugust 18, 2025 | msn.comStifel Nicolaus Keeps Their Buy Rating on Celcuity (CELC)August 18, 2025 | theglobeandmail.comCelcuity (NASDAQ:CELC) Given New $70.00 Price Target at Needham & Company LLCAugust 18, 2025 | americanbankingnews.comCelcuity (NASDAQ:CELC) Releases Earnings Results, Misses Expectations By $0.14 EPSAugust 17, 2025 | marketbeat.comCelcuity (NASDAQ:CELC) Price Target Cut to $70.00 by Analysts at Needham & Company LLCAugust 17, 2025 | marketbeat.comCelcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of "Buy" from AnalystsAugust 17, 2025 | marketbeat.comCelcuity Inc. (NASDAQ:CELC) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comCelcuity Expenses Jump 81 PercentAugust 16, 2025 | theglobeandmail.comCelcuity targets $5B addressable market as gedatolisib posts unprecedented PFS gains and patent extends to 2042August 16, 2025 | msn.comCelcuity Inc. (CELC) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comCelcuity (NASDAQ:CELC) Reaches New 52-Week High - Time to Buy?August 15, 2025 | marketbeat.comCelcuity reports Q2 EPS (93c), consensus (85c)August 14, 2025 | msn.comCelcuity shares fall as second quarter loss exceeds estimatesAugust 14, 2025 | investing.comCelcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comInsights into Celcuity's Upcoming EarningsAugust 13, 2025 | benzinga.comCelcuity (NASDAQ:CELC) Hits New 12-Month High - Still a Buy?August 10, 2025 | marketbeat.comCelcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference CallAugust 7, 2025 | globenewswire.comCelcuity (CELC) Projected to Post Earnings on WednesdayAugust 7, 2025 | marketbeat.comCelcuity Raises $248.7 Million Through Stock and NotesAugust 3, 2025 | theglobeandmail.comCelcuity Completes $201.25 Million Convertible Notes IssuanceAugust 2, 2025 | msn.comFY2026 EPS Estimates for Celcuity Boosted by HC WainwrightAugust 1, 2025 | marketbeat.comInsider Selling: Celcuity, Inc. (NASDAQ:CELC) Director Sells 100,000 Shares of StockJuly 31, 2025 | marketbeat.comCelcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 CatalystJuly 30, 2025 | seekingalpha.comCelcuity (NASDAQ:CELC) Shares Gap Down - Here's What HappenedJuly 30, 2025 | marketbeat.comCelcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast CancerJuly 30, 2025 | benzinga.comCelcuity prices $248.7M debt, stock offeringsJuly 30, 2025 | msn.comCelcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded WarrantsJuly 30, 2025 | globenewswire.comLeerink Partners Boosts Celcuity (NASDAQ:CELC) Price Target to $60.00July 29, 2025 | marketbeat.comSmall Cap Stocks To Keep An Eye On - July 28thJuly 29, 2025 | marketbeat.comCelcuity: What's Happening With CELC Stock?July 29, 2025 | forbes.comCelcuity Shares Surge on Positive Topline Results in Gedatolisib TrialJuly 29, 2025 | marketwatch.comCelcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows studyJuly 29, 2025 | msn.comWhy Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketJuly 28, 2025 | benzinga.comCelcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trialJuly 28, 2025 | msn.comCelcuity Shares Double After Landmark Breast Cancer Drug Trial ResultsJuly 28, 2025 | msn.comCelcuity Stock Triples on Positive Breast Cancer Treatment StudyJuly 28, 2025 | msn.comCelcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common StockJuly 28, 2025 | globenewswire.comPromising Biotech Stocks To Watch Today - July 28thJuly 28, 2025 | marketbeat.comCelcuity (NASDAQ:CELC) Price Target Raised to $50.00 at HC WainwrightJuly 28, 2025 | marketbeat.comCelcuity (NASDAQ:CELC) Sets New 12-Month High - Still a Buy?July 28, 2025 | marketbeat.comCelcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLCJuly 28, 2025 | marketbeat.comCelcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in studyJuly 28, 2025 | reuters.comCelcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 TrialJuly 28, 2025 | globenewswire.comCelcuity (NASDAQ:CELC) Sees Unusually-High Trading Volume - What's Next?July 26, 2025 | marketbeat.comCelcuity stock jumps ahead of pivotal breast cancer trial resultsJuly 26, 2025 | za.investing.com Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELC Media Mentions By Week CELC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CELC News Sentiment▼0.621.03▲Average Medical News Sentiment CELC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CELC Articles This Week▼53▲CELC Articles Average Week Get the Latest News and Ratings for CELC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Celcuity and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Guardant Health News Today RadNet News Today Sotera Health News Today Option Care Health News Today BrightSpring Health Services News Today GeneDx News Today Concentra Group Holdings Parent News Today Surgery Partners News Today Privia Health Group News Today Veracyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CELC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access